What typical antipsychotic is known for a high risk of extrapyramidal symptoms and low weight gain?

What typical antipsychotic is known for a high risk of extrapyramidal symptoms and low weight gain?

• A. Haldol
• B. Thorazine
• C. Prolixin
• D. Risperidone

Answer: (A)

The characteristic of the typical antipsychotic known for a high risk of extrapyramidal symptoms (EPS) and low weight gain is indeed Haldol, or haloperidol. Haldol is a butyrophenone antipsychotic that is widely used for its potency in treating psychotic disorders. One of the key side effects associated with typical antipsychotics, particularly those with higher potency like Haldol, is the development of extrapyramidal symptoms. These symptoms can include parkinsonism, akathisia, and tardive dyskinesia, which result from the medication's antagonistic effects on dopamine receptors in the brain. Additionally, Haldol is noted for its relatively lower propensity to cause weight gain compared to some other antipsychotics, particularly atypical ones. This is an important clinical consideration, especially for patients who may be concerned about metabolic side effects or who have a history of weight gain with other medications. While Thorazine (chlorpromazine) and Prolixin (fluphenazine) can also cause EPS, they are not as strongly associated with this side effect profile in comparison to Haldol. Thorazine is known for having a greater tendency to cause sedation and weight gain

The characteristic of the typical antipsychotic known for a high risk of extrapyramidal symptoms (EPS) and low weight gain is indeed Haldol, or haloperidol. Haldol is a butyrophenone antipsychotic that is widely used for its potency in treating psychotic disorders. One of the key side effects associated with typical antipsychotics, particularly those with higher potency like Haldol, is the development of extrapyramidal symptoms. These symptoms can include parkinsonism, akathisia, and tardive dyskinesia, which result from the medication's antagonistic effects on dopamine receptors in the brain.

Additionally, Haldol is noted for its relatively lower propensity to cause weight gain compared to some other antipsychotics, particularly atypical ones. This is an important clinical consideration, especially for patients who may be concerned about metabolic side effects or who have a history of weight gain with other medications.

While Thorazine (chlorpromazine) and Prolixin (fluphenazine) can also cause EPS, they are not as strongly associated with this side effect profile in comparison to Haldol. Thorazine is known for having a greater tendency to cause sedation and weight gain